NextCure Ownership
| NXTC Stock | USD 1.19 0.10 7.75% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 28 M | Current Value 28 M | Avarage Shares Outstanding 24.2 M | Quarterly Volatility 6.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
NextCure |
NextCure Stock Ownership Analysis
About 58.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NextCure has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 2.1. The firm had not issued any dividends in recent years. NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Nextcure operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. To find out more about NextCure contact Michael MSBA at 240 399 4900 or learn more at https://www.nextcure.com.Besides selling stocks to institutional investors, NextCure also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different NextCure's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align NextCure's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
NextCure Quarterly Liabilities And Stockholders Equity |
|
About 9.0% of NextCure are currently held by insiders. Unlike NextCure's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against NextCure's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of NextCure's insider trades
NextCure Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NextCure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NextCure backward and forwards among themselves. NextCure's institutional investor refers to the entity that pools money to purchase NextCure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Acuitas Investments, Llc | 2024-09-30 | 342.6 K | Federated Hermes Inc | 2024-09-30 | 321.5 K | Bml Capital Management Llc | 2024-09-30 | 276.5 K | Cardiff Park Advisors, Llc | 2024-06-30 | 262 K | Geode Capital Management, Llc | 2024-09-30 | 223.7 K | Macquarie Group Ltd | 2024-06-30 | 150 K | Sio Capital Management, Llc | 2024-09-30 | 130 K | Adar1 Capital Management Llc | 2024-09-30 | 120 K | Hudson Bay Capital Management Lp | 2024-09-30 | 107.7 K | Logos Global Management Lp | 2024-06-30 | 5 M | Sofinnova Ventures | 2024-06-30 | 2.7 M |
NextCure Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NextCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on NextCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NextCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NextCure Outstanding Bonds
NextCure issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NextCure uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NextCure bonds can be classified according to their maturity, which is the date when NextCure has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NextEra Energy Operating Corp BondUS65342QAB86 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| NextEra Energy Operating Corp BondUS65342QAL68 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| Nexstar Escrow 5625 Corp BondUS65343HAA95 | View | |
| US65342VAA98 Corp BondUS65342VAA98 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.10) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.